Prognostic Utility of Whole Genome **Sequencing and PCR in Post-procedure** Endophthalmitis



Sunir J. Garg, MD, FACS **Professor of Ophthalmology** MidAtlantic Retina, The Retina Service of Wills Eye Hospital **Thomas Jefferson University August 2020**



Disclosures

- Implant AG
- Consultant: Bausch and Lomb, Johnson & Johnson



• Research Support: Aerpio, Allergan, Apellis, Eyegate, Retina

• Many thanks to Cecilia Lee, MD and Russ VanGelder, MD, PhD





Summary

- Pathogen-negative and *S. epidermidis* endophthalmitis have better outcome than non-*S. Epidermidis* cases
- Bacterial load identified by WGS in non-S. *Epidermidis* cases are inversely associated with clinical outcome
- TTV is a significant risk factor for needing a secondary PPV
- Molecular data may be important predictors of poor clinical outcome



Introduction

- negative
 - qPCR 30% culture negative
- Up to 2/3 post-injection endophthalmitis culture-negative

Han et al. AJO 1996 Joseph et al. AJP 2012 Shah et al. Ophthalmology 2011

Approximately 30% of post-CE endophthalmitis is culture-



Emerging techniques for pathogen discovery in endophthalmitis

Bryan K. Hong¹, Cecilia S. Lee², Russell N. Van Gelder², and Sunir J. Garg¹

- Culture, 16S PCR, and BRiSK provide complementary information
- Culture-negative endophthalmitis cases do not have detectable bacterial DNA

- Small (3.8 kb), single-stranded DNA anellovirus
- Nearly ubiquitous
 - Viremia 2/3
- Associated with numerous chronic inflammatory conditions
 - MS, SLE, pulmonary fibrosis, asthma
 - SHAPU

Torque Teno Virus



hyperacule parayettis ar



Identification of Torque Teno Virus in Culture-Negative Endophthalmitis by **Representational Deep DNA Sequencing**

Aaron Y. Lee, MD, MSCI,¹ Lakshmi Akileswaran, PhD,² Michael D. Tibbetts, MD,⁵ Sunir J. Garg, MD,⁵ Russell N. Van Gelder, MD, PhD^{2,3,4}

- did some culture+
- extremely high (>10^7/ml)

• All culture- samples showed at least trace evidence of TTV, as

• Viral loads of Torque Teno virus varied but in some cases were



• Is TTV, along with other molecular data, associated with clinical outcome?

Purpose



- Post procedure endophthalmitis cases recruited prospectively
- Standard culture, quantitative PCR (qPCR) and whole genome sequencing (WGS) performed
- Outcomes: baseline, week 1, week 4, week 12

Methods

50 eyes: 24 culture-positive cases 26 culture-negative cases



Enterococcus faecalis (1) Streptococcus mitis (2)

Alpha-hemolytic Streptococcus (2)

S. lugdunensis (3)

S. epidermidis (11)

S. aureus (5)

	Culture positive (n=24)	Culture negative (n=26)	P-value
Mean age (range)	67 (44-85)	72 (36-98)	0.84
Male, n (%)	14 (58)	12 (46)	0.41
Intravitreal injections	16 (67)	14 (54)	0.43
Cataract surgeries	2 (8)	6 (23)	0.43
Median days to presentation (range)	5 (1-30)	8 (1-42)	0.14
Median baseline VA, logMAR	2.4 (HM)	2.4 (HM)	0.74
TTV presence (%)	8/22 (36)	15/25 (60)	0.15

- Of the 24 culture + cases, WGS identified the cultured bacteria in 3/4• WGS identified potential pathogens in 8/22 (36%) culture-negative cases
- (*S. epidermidis* (n=7) and *Pseudomonas* fluorescens (n=1))

Culture + vs - doesn't predict outcome



Culture positive







Pathogen Load

- Pathogen load for S. epi did not impact visual acuity
- However, higher baseline pathogen load for non S. epi was associated with worse vision at month 1 and 3

Torque Teno Virus

cases (p=0.147)

• TTV present in 8/22 (36%) of culture-positive and in 15/25 (60%) of culture-negative



TTV and Secondary PPV



10/23 (43%) in TTV + group
3/24 (13%) in TTV - group
OR 5.2 (95%Cl 1.07, 34.82, p=0.02)

All 5 cases that developed RD were TTV+



Conclusions

- Pathogen-negative and *S. epidermidis* endophthalmitis have better outcome than non-*S. Epidermidis* cases
- Bacterial load identified by WGS in non-S. *Epidermidis* cases are inversely associated with clinical outcome
- TTV is a significant risk factor for needing a secondary PPV
- Molecular data may be important predictors of poor clinical outcome

Acknowledgements/Funding

Endophthalmitis Study Group

Christopher Aderman, MD; Katherine Talcott, MD; Murtaza K Adam, MD; David S Ehmann, MD; Ferhina Ali, MD; James P. Dunn, MD; David H. Fisher, MD; Omesh Gupta, MD; Allen C. Ho, MD; Jason Hsu, MD; Michael Klufas, MD; Sonia Mehta, MD; Carl Park, MD; Carl D. Regillo, MD; Arunan Sivalingam, MD; Marc J. Spirn, MD; James Vander, MD, Kasra Rezaei, MD; Lisa Olmos de Koo, MD, MBA; Yewlin Chee, MD Funding Sources (U of Washington) NIH/NEI K23EY024921; NIH/NEI P30EY001730; Research to Prevent Blindness; Mark J. Daily, MD Research Grant

Thank you!